A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens. REVIVE-1

Trial Profile

A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens. REVIVE-1

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Iclaprim (Primary) ; Vancomycin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVE-1
  • Sponsors Motif Bio
  • Most Recent Events

    • 21 Dec 2017 Results published in the Motif Bio media release.
    • 21 Dec 2017 According to a Motif Bio media release, William O'Riordan, MD, FACEP, Chief Medical Officer is a principal investigator of the study.
    • 21 Dec 2017 According to a Motif Bio media release, results from this clinical trial has been published in the Clinical Infectious Diseases Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top